Heparin will just attempt to break up the clot and heparin agents do agents have some anti-inflammatory properties but not in the same league as MSCs. Like taking a knife to a gun fight.
Again, would be better to prevent the on-going damage which continues to spread through more organs, with more micro-emboli developing, which themselves are pro-inflammatory, by using MSCs. Makes sense to me.
Patients who are bed-bound are usually given DVT prophylaxis in any case, and can go from there to full anti-coagulation, which is considered on a case by case basis, but some Covid cases may be at risk of bleeding (perhaps counter-intuitively) complicating their management. So again, stop the clotting problem at its source (inflammation) with MSCs and you avoid potentially life threatening clotting vs treatment-related bleeding.
This dilemma occurs in treating cancer and in treating pre-eclampsia (an inflammatory condition associated with pregnancy), so we are used to the balancing act. If it can be avoided, eg now with MSCs in this condition (Covid-19/ARDS) that would be a game-changer, and most welcome. IMO.
- Forums
- ASX - By Stock
- Chances of Covid Trial being a success
MSB
mesoblast limited
Add to My Watchlist
0.93%
!
$1.63

Heparin will just attempt to break up the clot and heparin...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.63 |
Change
0.015(0.93%) |
Mkt cap ! $2.082B |
Open | High | Low | Value | Volume |
$1.63 | $1.67 | $1.61 | $6.975M | 4.265M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 707 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.64 | 7320 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 707 | 1.630 |
3 | 51200 | 1.625 |
15 | 159486 | 1.620 |
3 | 75310 | 1.615 |
11 | 90509 | 1.610 |
Price($) | Vol. | No. |
---|---|---|
1.635 | 7000 | 1 |
1.640 | 17668 | 3 |
1.645 | 20972 | 3 |
1.650 | 37309 | 4 |
1.655 | 45000 | 3 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online